- In July 2024, Merz Pharmaceuticals received FDA approval for an expanded indication of Xeomin (incobotulinumtoxinA) to include the treatment of blepharospasm alongside existing indications such as cervical dystonia and sialorrhea. This regulatory milestone reinforces Merz’s leadership in the botulinum toxin market and enhances access to a proven therapeutic option for patients suffering from involuntary eyelid spasms
- In February 2025, a clinical study published in ScienceDirect introduced a new combined preseptal and pretarsal botulinum toxin injection protocol for treating blepharospasm. The findings showed significant improvements in symptom relief and patient satisfaction compared to traditional injection techniques, representing a meaningful advancement in clinical practice
- In 2024, the Centers for Medicare & Medicaid Services (CMS) issued updated guidelines for the clinical use and reimbursement of botulinum toxin treatments for blepharospasm. These guidelines emphasized the use of standardized assessment tools such as the Jankovic Rating Scale (JRS) and Blepharospasm Disability Index (BSDI), while also setting clear parameters on dosing and documentation to ensure safe and effective use
